Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA
Zabel, M.
Acta Medica Polona 20(1): 53-54
1979
ISSN/ISBN: 0001-608X PMID: 495214 Document Number: 152123
Document emailed within 1 workday
Related Documents
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Clough, C.G.; Bergmann, K.J.; Yahr, M.D. 1984: Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration Advances in Neurology 40: 131-140
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Lun, A.; Szuecz, L.; Gross, J.; Horvath, G.; Nagy, I. 1989: Effect of mild postnatal hypoxia and L-dopa administration on dopamine concentration in striata of the newborn rat and long term sequelae on dopamine turnover Biomedica Biochimica Acta 48(2-3): S231-S236
Debreceni, L.; Hartmann, G. 1983: Effect of stress and cholinergic stimulation on ACTH release in alpha-methyl-dopa pretreated rats Acta Physiologica Hungarica 61(1-2): 99-103
Juvancz, P. 1981: The sleep of artificially reared newborn rats, effect of alpha-methyl-DOPA treatment on paradoxical sleep and on adult behaviour Acta Physiologica Academiae Scientiarum Hungaricae 57(1): 87-98
Martin, G.; Baumann, H. 1974: The effect of alpha-methyl dopa on the course of alloxan diabetes and the actual functional state of the CNS. 3. Bioelectric parameters (average evoked potentials) of hypothalamic structures resulting from visual stimulation Acta Biologica et Medica Germanica 33(3): 307-319
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Eisenlohr, J.J.; Gehlen, W. 1974: Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) Münchener Medizinische Wochenschrift 116(28): 1353-1356
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Quattrini, A.; Paggi, A.; Forastieri, L.; Del Pesce, M.; Di Bella, P. 1979: Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) Rivista di Patologia Nervosa e Mentale 99(5): 289-297